Performance of Screening Strategies for Latent Tuberculosis Infection in Patients with Inflammatory Bowel Disease: Results from the ENEIDA Registry of GETECCU

Riestra, Sabino ; Taxonera, Carlos ; Zabana, Yamile ; Carpio, Daniel ; Chaparro, María ; Barrio, Jesús ; Rivero, Montserrat ; López-Sanroman, Antonio ; Esteve, María ; de Francisco, Ruth ; Bastida, Guillermo ; García-López, Santiago (Universidad de Zaragoza) ; Mañosa, Miriam ; Martin-Arranz, María Dolores ; Pérez-Calle, José Lázaro ; Guardiola, Jordi ; Muñoz, Fernando ; Arranz, Laura ; Cabriada, José Luis ; García-Sepulcre, Mariana Fe ; Navarro, Mercè ; Montoro-Huguet, Miguel Ángel ; Ricart, Elena ; Bermejo, Fernando ; Calvet, Xavier ; Piqueras, Marta ; Garcia-Planella, Esther ; Márquez, Lucía ; Mínguez, Miguel ; Van Domselar, Manuel ; Bujanda, Luis ; Aldeguer, Xavier ; Sicilia, Beatriz ; Iglesias, Eva ; Alcaín, Guillermo ; Pérez-Martínez, Isabel ; Rolle, Valeria ; Castaño-García, Andrés ; P. Gisbert, Javier ; Domènech, Eugeni ;

Resumen: (1) Aims: Patients receiving antitumor necrosis factor (anti-TNF) therapy are at risk of developing tuberculosis (TB), usually due to the reactivation of a latent TB infection (LTBI). LTBI screening and treatment decreases the risk of TB. This study evaluated the diagnostic performance of different LTBI screening strategies in patients with inflammatory bowel disease (IBD). (2) Methods: Patients in the Spanish ENEIDA registry with IBD screened for LTBI between January 2003 and January 2018 were included. The diagnostic yield of different strategies (dual screening with tuberculin skin test [TST] and interferon-ץ-release assay [IGRA], two-step TST, and early screening performed at least 12 months before starting biological treatment) was analyzed. (3) Results: Out of 7594 screened patients, 1445 (19%; 95% CI 18–20%) had LTBI. Immunomodulator (IMM) treatment at screening decreased the probability of detecting LTBI (20% vs. 17%, p = 0.001). Regarding screening strategies, LTBI was more frequently diagnosed by dual screening than by a single screening strategy (IGRA, OR 0.60; 95% CI 0.50–0.73, p < 0.001; TST, OR 0.76; 95% CI 0.66–0.88, p < 0.001). Two-step TST increased the diagnostic yield of a single TST by 24%. More cases of LTBI were diagnosed by early screening than by routine screening before starting anti-TNF agents (21% [95% CI 20–22%] vs. 14% [95% CI 13–16%], p < 0.001). The highest diagnostic performance for LTBI (29%) was obtained by combining early and TST/IGRA dual screening strategies in patients without IMM. (4): Conclusions: Both early screening and TST/IGRA dual screening strategies significantly increased diagnostic performance for LTBI in patients with IBD, with optimal performance achieved when they are used together in the absence of IMM.

Idioma: Inglés

DOI: 10.3390/jcm11133915

Año: 2022

Publicado en: Journal of Clinical Medicine 11, 13 (2022), 3915 [12 pp.]
ISSN: 2077-0383

Factor impacto JCR: 3.9 (2022)

Categ. JCR: MEDICINE, GENERAL & INTERNAL rank: 58 / 169 = 0.343 (2022) - Q2 - T2

Factor impacto CITESCORE: 5.4 - Medicine (Q2)

Factor impacto SCIMAGO: 0.935 - Medicine (miscellaneous) (Q1)

Tipo y forma: Artículo (Versión definitiva)

Área (Departamento): Area Medicina (Dpto. Medicina, Psiqu. y Derm.)